| Primary |
| Malignant Melanoma |
32.8% |
| Hepatitis C |
30.1% |
| Product Used For Unknown Indication |
8.6% |
| Meningioma |
8.1% |
| Chronic Myeloid Leukaemia |
3.2% |
| Hypertension |
3.2% |
| Malignant Neoplasm Of Cornea |
1.6% |
| Pyrexia |
1.6% |
| Acute Lymphocytic Leukaemia |
1.1% |
| Bladder Cancer |
1.1% |
| Blood Pressure |
1.1% |
| Erdheim-chester Disease |
1.1% |
| Hypothyroidism |
1.1% |
| Myalgia |
1.1% |
| Mycosis Fungoides |
1.1% |
| Neuroendocrine Tumour |
1.1% |
| Arthritis |
0.5% |
| Benign Prostatic Hyperplasia |
0.5% |
| Crohn's Disease |
0.5% |
| Depression |
0.5% |
|
| Rash |
8.2% |
| Weight Decreased |
8.2% |
| Platelet Toxicity |
6.8% |
| Product Quality Issue |
6.8% |
| Pyrexia |
6.8% |
| Death |
5.5% |
| Overdose |
5.5% |
| Tremor |
5.5% |
| Vomiting |
5.5% |
| Drug Ineffective |
4.1% |
| Nausea |
4.1% |
| No Adverse Event |
4.1% |
| No Therapeutic Response |
4.1% |
| Pulmonary Arterial Hypertension |
4.1% |
| Thrombophlebitis |
4.1% |
| Treatment Noncompliance |
4.1% |
| Vaginal Haemorrhage |
4.1% |
| Anaemia |
2.7% |
| Blood Triglycerides Increased |
2.7% |
| Depression |
2.7% |
|
| Secondary |
| Hepatitis C |
51.5% |
| Malignant Melanoma |
8.2% |
| Hypertension |
7.6% |
| Blood Pressure |
7.0% |
| Product Used For Unknown Indication |
4.7% |
| Nausea |
3.5% |
| Metastatic Malignant Melanoma |
2.9% |
| Acute Lymphocytic Leukaemia |
2.3% |
| Pyrexia |
1.8% |
| Bladder Cancer |
1.2% |
| Chronic Hepatitis C |
1.2% |
| Chronic Myeloid Leukaemia |
1.2% |
| Multiple Myeloma |
1.2% |
| Mycosis Fungoides |
1.2% |
| Neuroendocrine Tumour |
1.2% |
| Pain |
1.2% |
| Benign Prostatic Hyperplasia |
0.6% |
| Diabetes Mellitus |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
0.6% |
|
| Salmonella Sepsis |
11.8% |
| Vomiting |
11.8% |
| Pyrexia |
9.8% |
| Sepsis |
7.8% |
| White Blood Cell Count Decreased |
7.8% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.9% |
| Drug Ineffective |
3.9% |
| Hepatitis C |
3.9% |
| Intestinal Haemorrhage |
3.9% |
| Off Label Use |
3.9% |
| Osteonecrosis Of Jaw |
3.9% |
| Product Packaging Quantity Issue |
3.9% |
| Pulmonary Arterial Hypertension |
3.9% |
| Therapeutic Response Decreased |
3.9% |
| Weight Decreased |
3.9% |
| Hypothyroidism |
2.0% |
| Induration |
2.0% |
| Malaise |
2.0% |
| Malignant Neoplasm Progression |
2.0% |
| Nausea |
2.0% |
|
| Concomitant |
| Multiple Myeloma |
33.3% |
| Neuroendocrine Tumour |
16.7% |
| Osteoporosis |
16.7% |
| Premedication |
16.7% |
| Renal Cancer |
16.7% |
|
| Blood Pressure Increased |
20.0% |
| Dizziness |
20.0% |
| Osteonecrosis Of Jaw |
20.0% |
| Product Quality Issue |
20.0% |
| Weight Decreased |
20.0% |
|
